Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. DiNardo CD, et al. Among authors: cortes je. Leukemia. 2014 Apr;28(4):958-61. doi: 10.1038/leu.2014.8. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24492324 Free PMC article. No abstract available.
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Ravandi F, Arana Yi C, Cortes JE, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H. Ravandi F, et al. Among authors: cortes je. Leukemia. 2014 Jul;28(7):1543-5. doi: 10.1038/leu.2014.54. Epub 2014 Feb 3. Leukemia. 2014. PMID: 24487412 Free PMC article. Clinical Trial. No abstract available.
Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z, Cortes JE, Jorgensen JL, Wang W, Yin CC, You MJ, Jabbour E, Kantarjian HM, Medeiros LJ, Hu S. Chen Z, et al. Among authors: cortes je. Leukemia. 2016 Jul;30(7):1606-9. doi: 10.1038/leu.2016.6. Epub 2016 Feb 3. Leukemia. 2016. PMID: 26837843 Free PMC article. No abstract available.
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G. Al-Kali A, et al. Am J Hematol. 2013 May;88(5):365-9. doi: 10.1002/ajh.23410. Epub 2013 Mar 20. Am J Hematol. 2013. PMID: 23512829 Free PMC article.
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Daver N, et al. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):435-40. doi: 10.1016/j.clml.2013.02.021. Epub 2013 Jun 10. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23763915 Free PMC article.
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.
Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. Daver N, et al. Among authors: cortes je. Eur J Cancer Care (Engl). 2013 Sep;22(5):605-11. doi: 10.1111/ecc.12065. Epub 2013 May 23. Eur J Cancer Care (Engl). 2013. PMID: 23701251 Free PMC article. Clinical Trial.
453 results